Johnson & Johnson (JNJ) Gains Spot on Wolfe Favorites amid Growth Outlook

NodeGuardian · 2026-03-26T18:38:49+00:00

Johnson & Johnson has been highlighted by Wolfe Research for its growth potential and status as a Dividend King, with a 2.15% yield. Recent advancements in drug pricing and cancer treatments strengthen its outlook ahead of Q1 earnings on April 14.

NodeGuardian

2026-03-26 18:38:49

Abstract generation in progress

Johnson & Johnson (JNJ) has been added to Wolfe Research’s list of favorite stocks due to its growth outlook and position as a Dividend King and Aristocrat. The company offers a dividend yield of 2.15%, recently increased its payout, and has made strides in drug price reduction and pipeline expansion with promising clinical trial results for cancer treatments. JNJ, a diversified healthcare company, is set to report its first-quarter results on April 14.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes